Stockscreener 앱 받기
5.99
0.84%
0.05
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Form 8K Phathom Pharmaceuticals Inc For: 26 October By Investing.com - Investing.com UK
Comments on the FDA’s VOQUEZNA docket close November 23, 2026, Phathom (PHAT) says. - Stock Titan
Phathom Pharmaceuticals Provides Update on FDA Litigation - GlobeNewswire Inc.
Phathom Pharmaceuticals reports lawsuit over Voquezna exclusivity - Investing.com
Form 8K Phathom Pharmaceuticals Inc For: 23 October By Investing.com - Investing.com Australia
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA - GlobeNewswire Inc.
Phathom Pharmaceuticals, Inc. (PHAT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phathom Pharmaceuticals to Host Third Quarter 2026 Financial Results Webcast on October 29 - Quiver Quantitative
Jefferies cuts Phathom Pharmaceuticals price target on 2027 outlook - Investing.com
Phathom Pharmaceuticals Highlights New Cost-Effectiveness - GlobeNewswire
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026 - Yahoo! Finance Canada
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com UK
For tax withholding, Phathom (PHAT) CFO surrenders 13,485 shares at $6.78 each. - Stock Titan
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com Nigeria
BXP Director Julie Richardson Purchases 409.1 Phantom Stock Units - Kalkine Media
Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Canada
Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD By Investing.com - Investing.com South Africa
Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD - Investing.com UK
Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phathom Pharmaceuticals Initiates Phase 3 Study of VOQUEZNA for As-Needed Treatment of Non-Erosive GERD - Quiver Quantitative
Heartburn medicine taken only when symptoms strike is being tested in a new study. - Stock Titan
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Yahoo Finance
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals targets gastroenterolog... - Pluang
PHAT Initiates Coverage On Leerink Partners -- Rating Set to Mar - GuruFocus
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) - Seeking Alpha
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com Canada
Phathom at Cantor conference: growth, access and new uses - Investing.com
PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10 - Moomoo
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT - marketscreener.com
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Stocktwits
Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT? - StockInvest.us
PHAT stock holds near 9 dollars as Q2 loss narrows and revenue rises - ad-hoc-news.de
PHAT stock trades quietly as Phathom Pharmaceuticals prepares next data releases - ad-hoc-news.de
Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences - Traders Union
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - finance.yahoo.com
4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc. - MarketBeat
Phathom Pharmaceuticals Inc. (PHAT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phathom Pharmaceuticals Inc. (PHAT) Peer Comparison – Compare with Others - Value Research
Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Gains 2.68% to $9.18, Nearing Resistance at $9.64OBV Trend Line - www.dars.gov.et
Phathom (PHAT) Today: Moves 3.14% Higher to $8.87 in the Latest Session; Current Setup: the Session Ends Within the Reported Technical Boundaries at the CloseFibonacci Entry Signals - siam.in
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN) - theglobeandmail.com
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
5.91%
2.85%
자본화:
|
볼륨(24시간):